A study comparing patients undergoing recanalization for chronic total occlusions (CTO)with either Orsiro Sirolimus-eluting stent (O-SES) or Zotarolimus-eluting stent (ZES)

Trial Profile

A study comparing patients undergoing recanalization for chronic total occlusions (CTO)with either Orsiro Sirolimus-eluting stent (O-SES) or Zotarolimus-eluting stent (ZES)

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2016

At a glance

  • Drugs Sirolimus (Primary) ; Zotarolimus
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top